• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by INmune Bio Inc.

    2/15/23 5:06:34 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INMB alert in real time by email
    SC 13G 1 inmunebioinc-xencorsc13g20.htm SC 13G Document

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    INmune Bio, Inc.
    (Name of Issuer)
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
    45782T105
    (CUSIP Number)
    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐Rule 13d-1(b)
    ☐Rule 13d-1(c)
    ☒Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





    CUSIP No. 45782T105
     
      1   
      NAMES OF REPORTING PERSONS
     Xencor, Inc.
      2 
      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)  ☐        (b)  ☒
     
      3 
      SEC USE ONLY
     
      4 
      CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
    NUMBER OF
    SHARES
     BENEFICIALLY 
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
      5    
      SOLE VOTING POWER
     
      1,885,533
      6  
      SHARED VOTING POWER
     
      0
      7  
      SOLE DISPOSITIVE POWER
     
      1,885,533
      8  
      SHARED DISPOSITIVE POWER
     
      0
      9   
      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      1,885,533
    10 
      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
      ☐
    11 
      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
      10.5%(1)
    12 
      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
      CO

    (1)     This percentage is calculated based upon 17,945,995 shares of the Issuer’s Common Stock outstanding as set forth in the Issuer’s Form 10-Q for the third quarter ended September 30, 2022, filed with the Securities and Exchange Commission on November 2, 2022.


    Item 1(a).    Name of Issuer:
    INmune Bio, Inc.



    Item 1(b).    Address of Issuer’s Principal Executive Offices:
    225 NE Mizner Blvd., Suite 640,
    Boca Raton, FL 33432
    Item 2(a).    Name of Person Filing:
    Xencor, Inc.
    (the “Reporting Person”)
    Item 2(b).    Address of Principal Business Office or, if none, Residence:

    The address of the principal business office of the Reporting Person is:
    111 West Lemon Avenue
    Monrovia, California 91016
    Item 2(c).    Citizenship:
    The Reporting Person is a corporation organized under the laws of the State of Delaware.
    Item 2(d).    Title of Class of Securities:
    Common Stock, par value $0.001 per share (“Common Stock”)
    Item 2(e).    CUSIP Number:
    45782T105
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable
    Item 4.    Ownership

    The Reporting Person directly holds 1,885,533 shares of Common Stock. The information required by this item with respect to the Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G/A.
    Item 5.    Ownership of 5 Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
    Item 6.    Ownership of More than 5 Percent on Behalf of Another Person:
    Not applicable
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:
    Not applicable
    Item 8.    Identification and Classification of Members of the Group:
    Not applicable
    Item 9.    Notice of Dissolution of a Group:
    Not applicable
    Item 10.    Certifications:
    Not applicable




    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated: February 15, 2023
    XENCOR, INC.

    By:
    /s/ John J. Kuch
    John J. Kuch,
    Senior Vice President and Chief Financial Officer


    ATTENTION:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)



    Get the next $INMB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INMB

    DatePrice TargetRatingAnalyst
    7/1/2025$0.60Sector Outperform → Sector Underperform
    Scotiabank
    7/1/2025Buy → Neutral
    BTIG Research
    1/28/2025$23.00Buy
    Rodman & Renshaw
    10/21/2024$20.00Buy
    Alliance Global Partners
    9/27/2024$18.00Outperform
    Raymond James
    8/22/2024$22.00Sector Outperform
    Scotiabank
    6/1/2023$16.00Outperform
    Robert W. Baird
    5/24/2022$14.00 → $7.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $INMB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

      Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the "Offering") for the purchase and sale of 3,000,000 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds from the Offering are approximately $19 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the Offering for working capital purposes and general corporate procedures. A.G.P./All

      6/30/25 4:05:00 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

      In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro™ treatment over placebo was observed in cognitive, behavioral and biological endpoints. Treatment with XPro™ was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients. The most common adverse events (AE) were injection site reactions. Additional analyses w

      6/30/25 7:30:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

      Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. The closing of the Offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $19 million,

      6/27/25 12:16:00 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • INmune Bio downgraded by BTIG Research

      BTIG Research downgraded INmune Bio from Buy to Neutral

      7/1/25 8:14:45 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio downgraded by Scotiabank with a new price target

      Scotiabank downgraded INmune Bio from Sector Outperform to Sector Underperform and set a new price target of $0.60

      7/1/25 8:14:45 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on INmune Bio with a new price target

      Rodman & Renshaw initiated coverage of INmune Bio with a rating of Buy and set a new price target of $23.00

      1/28/25 7:14:13 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INMB
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by INmune Bio Inc.

      SCHEDULE 13G - Inmune Bio, Inc. (0001711754) (Subject)

      7/2/25 10:09:26 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Inmune Bio, Inc. (0001711754) (Filer)

      6/30/25 4:31:00 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by INmune Bio Inc.

      424B5 - Inmune Bio, Inc. (0001711754) (Filer)

      6/30/25 9:15:17 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ganjei James Kelly

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:24 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Juda Scott

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:27 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Allen Marcia

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      12/9/24 4:00:27 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Moss David J bought $52,868 worth of shares (10,000 units at $5.29), increasing direct ownership by 0.78% to 1,285,869 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/30/24 4:01:02 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Tesi Raymond Joseph bought $98,048 worth of shares (15,380 units at $6.38), increasing direct ownership by 1.00% to 1,554,106 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/16/24 8:48:44 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Moss David J bought $49,024 worth of shares (7,690 units at $6.38), increasing direct ownership by 0.61% to 1,275,869 units (SEC Form 4)

      4 - Inmune Bio, Inc. (0001711754) (Issuer)

      9/16/24 8:47:21 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INMB
    Leadership Updates

    Live Leadership Updates

    See more
    • INmune Bio Inc. to Join Russell 3000® Index

      Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion

      5/30/24 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

      DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company's board of directors. "As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy," stated Dr. Charles Nicolette, chief executive officer. "In his new role as chairman, his depth of experience in both biotechnology and fundraising will provide new levels of insight and guidance as we seek to advance our novel pipeline o

      11/15/21 8:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by INmune Bio Inc.

      SC 13G - Inmune Bio, Inc. (0001711754) (Subject)

      10/25/24 10:15:45 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by INmune Bio Inc.

      SC 13G/A - Inmune Bio, Inc. (0001711754) (Subject)

      10/2/24 4:50:56 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by INmune Bio Inc.

      SC 13G - Inmune Bio, Inc. (0001711754) (Subject)

      2/15/23 5:06:34 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INMB
    Financials

    Live finance-specific insights

    See more
    • INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

      In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro™ treatment over placebo was observed in cognitive, behavioral and biological endpoints. Treatment with XPro™ was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients. The most common adverse events (AE) were injection site reactions. Additional analyses w

      6/30/25 7:30:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

      Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025 Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, will host a conference call on Monday, June 30 beginning at 8:00am EDT to present top line data from the Phase 2 MINDFuL trial in early Alzheimer's Disease. MINDFuL Results Call Information: To participate in this event, dial approximately at least 10 minutes before the beginning of the call or use the webcast link below. Please ask for the INmune Bio MINDFuL Conference Call when reaching the operator. Date: June 30, 2025 Time: 8:00 AM Eastern Tim

      6/26/25 4:00:00 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

      Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 8th, 2025 at 4:30pm EDT to discuss results for its quarter ended March 31, 2025 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. Date: May 8th, 2025 Time: 4:30 PM Eastern Tim

      5/5/25 7:00:00 AM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INMB
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

      Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

      6/26/24 2:54:12 PM ET
      $INMB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care